Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA clears Zomig

Nov. 27, 1997

Launch of Ligand/Lilly metabolic disease alliance

Nov. 27, 1997

Tolcapone reduces "wearing-off" phenomonen in Parkinson's disease patients

Nov. 27, 1997

RPR merger with Rhone-Poulenc finalized

Nov. 27, 1997

Controlled trial of ofloxacin + IFN-alpha-2b in chronic hepatitis C

Nov. 27, 1997

SB-205384 associated with temporal modulation of GABA-gated currents

Nov. 27, 1997

Profile of hepatoprotective activity of picroliv in rats

Nov. 27, 1997

Abbott improves on the pharmacological profiles of its ChCM candidates

Nov. 27, 1997

Pharmacological profile of TH-142177, a new AT1 receptor antagonist

Nov. 27, 1997

Cathepsin L inhibitors with broad therapeutic potential from Takeda

Nov. 27, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...